Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abivax SA Sponsored ADR (ABVX)
NASDAQ:ABVX
Holding ABVX?
Track your performance easily
ABVX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.54 - $17.02
Previous CloseN/A
Volume62.24K
Average Volume (3M)194.98K
Market Cap
$405.94M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Mar 13, 2025EPS Estimate
-0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.55
Shares Outstanding63,365,566
10 Day Avg. Volume135,967
30 Day Avg. Volume194,983
Standard Deviation0.11
R-Squared0.03
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)83.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$32.50Price Target Upside444.39% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Abivax SA Sponsored ADR News
PremiumCompany Announcements
Abivax Initiates $150 Million ATM Program on Nasdaq
PremiumCompany Announcements
Abivax Reports Strong Q3 Financials and Clinical Progress
PremiumCompany Announcements
Abivax SA Unveils New Ulcerative Colitis Treatment Data
PremiumCompany Announcements
Abivax Reports Progress in Ulcerative Colitis Therapy
Bulls Say, Bears Say
Bulls Say
Clinical TrialsObefazimod's clinical profile, including high rates of clinical remission and a generally clean safety profile in a convenient oral form, remains compelling.
Financial StabilityThe company reiterated that its current cash is sufficient to fund operations into 4Q25, beyond the readout of the Phase 3 induction results.
Market PotentialThe commercial potential for obefazimod is compelling, with an opportunity to position as an early treatment option among advanced therapies for IBD.
Bears Say
Guidance UpdateManagement updated guidance for enrollment completion for obefazimod's Phase 3 trial in UC to 2Q25, subsequently shifting topline readout for induction data to 3Q25.
Phase 3 Trial TimelineThe timeline for the Phase 3 trial of obefazimod in ulcerative colitis has been pushed back, with topline data now expected later than previously guided.
Trial DelaysThe company now expects to complete enrollment in 2Q25, an approx. one quarter delay from prior guidance as the study contends with a highly competitive trial recruitment environment in UC.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
0.80% Mutual Funds
<0.01% Other Institutional Investors
99.20% Public Companies and Individual Investors
ABVX FAQ
What was Abivax SA Sponsored ADR’s price range in the past 12 months?
Abivax SA Sponsored ADR lowest stock price was $5.54 and its highest was $17.02 in the past 12 months.
What is Abivax SA Sponsored ADR’s market cap?
Abivax SA Sponsored ADR’s market cap is $405.94M.
When is Abivax SA Sponsored ADR’s upcoming earnings report date?
Abivax SA Sponsored ADR’s upcoming earnings report date is Mar 13, 2025 which is in 39 days.
How were Abivax SA Sponsored ADR’s earnings last quarter?
Abivax SA Sponsored ADR released its earnings results on Nov 07, 2024. The company reported -$0.72 earnings per share for the quarter, beating the consensus estimate of -$0.723 by $0.003.
Is Abivax SA Sponsored ADR overvalued?
According to Wall Street analysts Abivax SA Sponsored ADR’s price is currently Undervalued.
Does Abivax SA Sponsored ADR pay dividends?
Abivax SA Sponsored ADR does not currently pay dividends.
What is Abivax SA Sponsored ADR’s EPS estimate?
Abivax SA Sponsored ADR’s EPS estimate is -0.75.
How many shares outstanding does Abivax SA Sponsored ADR have?
Abivax SA Sponsored ADR has 63,365,566 shares outstanding.
What happened to Abivax SA Sponsored ADR’s price movement after its last earnings report?
Abivax SA Sponsored ADR reported an EPS of -$0.72 in its last earnings report, beating expectations of -$0.723. Following the earnings report the stock price went down -0.664%.
Which hedge fund is a major shareholder of Abivax SA Sponsored ADR?
Currently, no hedge funds are holding shares in ABVX
---
Abivax SA Sponsored ADR Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.50 (444.39% Upside)
$32.50 (444.39% Upside)
Hedge Fund Trend
Decreased
By 289.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 7.0%
Last 30 Days ▼ 10.0%
Last 30 Days ▼ 10.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.78%
12-Months-Change
Fundamentals
Return on Equity
-171.78%
Trailing 12-Months
Asset Growth
63.36%
Trailing 12-Months
Company Description
Abivax SA Sponsored ADR
Abivax is focused on developing innovative treatments that harness the body¿s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
---
ABVX Stock 12 Month Forecast
Average Price Target
$32.50
▲(444.39% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Ionis Pharmaceuticals
―
Neurocrine
―
Regeneron
―
Vertex Pharmaceuticals
―
Best Analysts Covering ABVX
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-38.51%
reiterated a buy rating 23 days ago
Copying Sam Slutsky's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -38.51% per trade.
---